Abstract
Peroxisome proliferator-activated receptor gamma (PPAR-
Peroxisome proliferator-activated receptor gamma (PPAR-
C. Blanquart, O. Fruchart, B. Fruchart, B. Steals, and C. Glineur, “Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, pp. 267–273, 2003.
View at: Publisher Site | Google ScholarS. R. Farmer, “Regulation of PPAR activity during adipogenesis,” International Journal of Obesity, vol. 29, 1, pp. 13–16, 2005.
View at: Publisher Site | Google ScholarS. L. Gray, E. Dalla Nora, and A. J. Vidal-Puig, “Mouse models of PPAR- deficiency: dissecting PPAR-'s role in metabolic homoeostasis,” Biochemical Society Transactions, vol. 33, no. 5, pp. 1053–1058, 2005.
View at: Publisher Site | Google ScholarM. Gurnel, “Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 19, no. 4, pp. 501–523, 2005.
View at: Publisher Site | Google ScholarB. P. Kota, T. H. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 58–94, 2005.
View at: Publisher Site | Google ScholarM. A. Lazar, “PPAR gamma, 10 years later,” Biochimie, vol. 87, no. 1, pp. 9–13, 2005.
View at: Publisher Site | Google ScholarM. Lehrke and M. A. Lazar, “The many faces of PPARgamma,” Cell, vol. 123, no. 6, pp. 993–999, 2005.
View at: Publisher Site | Google ScholarS. Miard and L. Fajas, “Atypical transcriptional regulators and cofactors of PPAR-,” International Journal of Obesity, vol. 29, 1, pp. 10–12, 2005.
View at: Publisher Site | Google ScholarL. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology & Therapeutics, vol. 110, no. 3, pp. 371–385, 2006.
View at: Publisher Site | Google ScholarR. K. Semple, V. K. Chatterjee, and S. O'Rahilly, “PPAR- and human metabolic disease,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 581–589, 2006.
View at: Publisher Site | Google ScholarB. Staels and J. C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005.
View at: Publisher Site | Google ScholarN. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 93, no. 2–5, pp. 99–105, 2005.
View at: Publisher Site | Google ScholarS. Theocharis, A. Margeli, P. Vielh, and G. Kouraklis, “Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators,” Cancer Treatment Reviews, vol. 30, no. 6, pp. 545–554, 2004.
View at: Publisher Site | Google ScholarR. Mukherjee, L. Jow, G. E. Croston, and J. R. Paterniti Jr., “Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR-2 versus PPAR-1 and activation with retinoid X receptor agonists and antagonists,” The Journal of Biological Chemistry, vol. 272, no. 12, pp. 8071–8076, 1997.
View at: Publisher Site | Google ScholarY. Zhu, C. Qi, J. R. Korenberg et al., “Structural organization of mouse peroxisome proliferator-activated receptor- (mPPAR-) gene: alternative promoter use and different splicing yield two mPPAR- isoforms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7921–7925, 1995.
View at: Publisher Site | Google ScholarY. Barak, M. C. Nelson, E. S. Ong et al., “PPAR is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999.
View at: Publisher Site | Google ScholarE. D. Rosen, P. Sarraf, A. E. Troy et al., “PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999.
View at: Publisher Site | Google ScholarP. Tontonoz, E. Hu, R. A. Graves, A. L. Budavari, and B. M. Spiegelman, “mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer,” Genes & Development, vol. 8, no. 10, pp. 1224–1234, 1994.
View at: Publisher Site | Google ScholarA. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994.
View at: Publisher Site | Google ScholarK. Schoonjans, J. Peinado-Onsurbe, A. M. Lefebvre et al., “PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” The EMBO Journal, vol. 15, pp. 5336–5348, 1996.
View at: Google ScholarP. Tontonoz, E. Hu, J. Devine, E. G. Beale, and B. M. Spiegelman, “PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene,” Molecular and Cellular Biology, vol. 15, no. 1, pp. 351–357, 1995.
View at: Google ScholarB. I. Frohnert, T. Y. Hui, and D. A. Bernlohr, “Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene,” The Journal of Biological Chemistry, vol. 274, no. 7, pp. 3970–3977, 1999.
View at: Publisher Site | Google ScholarC. W. Miller and J. M. Ntambi, “Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9443–9448, 1996.
View at: Publisher Site | Google ScholarB. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-Deoxy-, is a ligand for the adipocyte determination factor PPAR-,” Cell, vol. 83, no. 5, pp. 803–812, 1995.
View at: Publisher Site | Google ScholarS. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. Morris, and J. M. Lehmann, “A prostaglandin metabolite binds peroxisome proliferator-activated receptor- and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995.
View at: Publisher Site | Google ScholarS. Altiok, M. Xu, and B. M. Spiegelman, “PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A,” Genes & Development, vol. 11, no. 15, pp. 1987–1998, 1997.
View at: Google ScholarJ. M. Gimble, C. E. Robinson, X. Wu et al., “Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells,” Molecular Pharmacology, vol. 50, no. 5, pp. 1087–1094, 1996.
View at: Google ScholarE. Hu, P. Tontonoz, and P. M. Spiegelman, “Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR- and C/,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, pp. 9856–9860, 1995.
View at: Publisher Site | Google ScholarJ. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma),” The Journal of Biological Chemistry, vol. 270, no. 50, pp. 12953–12956, 1995.
View at: Publisher Site | Google ScholarP. Tontonoz, E. Hu, and P. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994.
View at: Publisher Site | Google ScholarT. Akune, S. Ohba, S. Kamekura et al., “PPAR- insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” The Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004.
View at: Publisher Site | Google ScholarS. P. Bruder, N. Jaiswal, and S. E. Haynesworth, “Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation,” Journal of Cellular Biochemistry, vol. 64, no. 2, pp. 278–294, 1997.
View at: Publisher Site | Google ScholarJ. J. Minguell, A. Erices, and P. Conget, “Mesenchymal stem cells,” Experimental Biology and Medicine, vol. 226, pp. 507–520, 2001.
View at: Google ScholarM. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999.
View at: Publisher Site | Google ScholarD. J. Prockop, “Marrow stromal cells as stem cells for nonhematopoietic tissues,” Science, vol. 276, no. 5309, pp. 71–74, 1997.
View at: Publisher Site | Google ScholarS. Ahdjoudj, F. Lasmoles, B. O. Oyajobi, A. Lomri, P. Delannoy, and P. J. Marie, “Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation of multipotential clonal human marrow stromal F/STRO-1(+) cells,” Journal of Cellular Biochemistry, vol. 81, no. 1, pp. 23–38, 2001.
View at: Publisher Site | Google ScholarT. Akune, S. Ohba, S. Kamekura et al., “PPAR insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” The Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004.
View at: Publisher Site | Google ScholarJ. N. Beresford, J. H. Bennett, C. Devlin, P. S. Leboy, and M. E. Owen, “Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures,” Journal of Cell Science, vol. 83, no. 102, pt. 2, pp. 341–351, 1992.
View at: Google ScholarF. Gori, T. Thomas, K. C. Hicok, T. C. Spelsberg, and B. L. Riggs, “Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation,” Journal of Bone and Mineral Research, vol. 14, pp. 1522–1535, 1999.
View at: Publisher Site | Google ScholarR. K. Jaiswal, N. Jaiswal, S. P. Bruder, G. Mbalaviele, D. R. Marshak, and M. F. Pittenger, “Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase,” The Journal of Biological Chemistry, vol. 275, no. 13, pp. 9645–9652, 2000.
View at: Publisher Site | Google ScholarB. Lecka-Czernik, E. J. Moerman, D. F. Grant, J. M. Lehmann, S. C. Manolagas, and R. L. Jilka, “Divergent effects of selective peroxisome proliferator-activated receptor-2 ligands on adipocyte versus osteoblast differentiation,” Endocrinology, vol. 143, no. 6, pp. 2376–2384, 2002.
View at: Publisher Site | Google ScholarM. E. Nuttall and J. M. Gimble, “Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?” Bone, vol. 27, no. 2, pp. 177–184, 2000.
View at: Publisher Site | Google ScholarA. C. Maurin, P. M. Chavassieux, L. Frappart, P. D. Delmas, C. M. Serre, and P. J. Meunier, “Influence of mature adipocytes on osteoblast proliferation in human primary cocultures,” Bone, vol. 26, no. 5, pp. 485–489, 2000.
View at: Publisher Site | Google ScholarS. K. Fried, D. A. Bunkin, and A. S. Greenberg, “Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid,” The Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 3, pp. 847–850, 1998.
View at: Publisher Site | Google ScholarS. Verma, J. H. Rajaratnam, J. Denton, J. A. Hoyland, and R. J. Byers, “Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis,” Journal of Clinical Pathology, vol. 55, no. 9, pp. 693–698, 2002.
View at: Publisher Site | Google ScholarJ. Justesen, K. Stenderup, and M. S. Kassem, “Mesenchymal stem cells. Potential use in cell and gene therapy of bone loss caused by aging and osteoporosis,” Ugeskrift for Laeger, vol. 163, no. 40, pp. 5491–5495, 2001.
View at: Google ScholarA. Grey, M. Bolland, G. Gamble et al., “The peroxisome proliferator-activated receptor- agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 4, pp. 1305–1310, 2007.
View at: Publisher Site | Google ScholarA. V. Schwartz, “Diabetes, TZDs, and Bone,” A Review of the Clinical Evidence, vol. 2006, Article ID 24502, 2006.
View at: Google ScholarS. Miard and L. Fajas, “Atypical transcriptional regulators and cofactors of PPAR,” International Journal of Obesity, vol. 29, 1, pp. 10–12, 2005.
View at: Publisher Site | Google ScholarE. D. Rosen and L. Fajas, “Atypical transcriptional regulators and cofactors of PPAR,” Prostaglandins, Leukotrienes, and Essential Fatty Acids, vol. 73, no. 1, pp. 31–34, 2005.
View at: Publisher Site | Google ScholarC. W. Park, H. W. Kim, S. H. Ko et al., “Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1227–1238, 2007.
View at: Publisher Site | Google ScholarJ. A. Clowes, S. Khosla, R. Eastell et al., “Potential role of pancreatic and enteric hormones in regulating bone turnover,” Journal of Bone and Mineral Research, vol. 20, no. 9, pp. 1497–1506, 2005.
View at: Publisher Site | Google ScholarI. R. Reid, J Cornish, and P. A. Baldock, “Nutrition-related peptides and bone homeostasis,” Journal of Bone and Mineral Research, vol. 21, no. 4, pp. 495–500, 2006.
View at: Publisher Site | Google ScholarN. A. Tritos and E. G. Kokkotou, “The physiology and potential clinical applications of ghrelin, a novel peptide hormone,” Mayo Clinic Proceedings, vol. 81, no. 5, pp. 653–660, 2006.
View at: Google ScholarN. Fukushima, R. Hanada, H. Teranishi et al., “Ghrelin directly regulates bone Formation,” Journal of Bone and Mineral Research, vol. 20, no. 5, pp. 790–798, 2005.
View at: Publisher Site | Google ScholarS. W. Kim, S. J. Her, S. J. Park et al., “Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells,” Bone, vol. 37, no. 3, pp. 359–369, 2005.
View at: Publisher Site | Google ScholarM. S. Huda, B. H. Durham, S. P. Wong et al., “Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects,” Bone, vol. 41, no. 3, pp. 406–413, 2007.
View at: Publisher Site | Google ScholarL. A. Weiss, C. Langenberg, E. Barrett-Connor et al., “Ghrelin and bone: is there an association in older adults?: the Rancho Bernardo study,” Journal of Bone and Mineral Research, vol. 21, no. 5, pp. 752–757, 2006.
View at: Publisher Site | Google ScholarL. L. Baggio and D. J. Drucker, “Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 18, no. 4, pp. 531–554, 2004.
View at: Publisher Site | Google ScholarD. B. Henriksen, P. Alexandersen, N. H. Bjarnason et al., “Role of gastrointestinal hormones in postprandial reduction of bone resorption,” Journal of Bone and Mineral Research, vol. 18, no. 12, pp. 2180–2189, 2003.
View at: Publisher Site | Google ScholarD. B. Henriksen, P. Alexandersen, I. Byrjalsen et al., “Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2,” Bone, vol. 34, no. 1, pp. 140–147, 2004.
View at: Publisher Site | Google ScholarD. B. Henriksen, P. Alexandersen, B. Hartmann et al., “Disassociation of bone resorption and formation by GLP-2A 14-day study in healthy postmenopausal women,” Bone, vol. 40, no. 3, pp. 723–729, 2007.
View at: Publisher Site | Google ScholarN. H. Bjarnason, E. E. Henriksen, P. Alexandersen, S. Christgau, D. B. Henriksen, and C. Christiansen, “Mechanism of circadian variation in bone resorption,” Bone, vol. 30, no. 1, pp. 307–313, 2002.
View at: Publisher Site | Google ScholarJ. Cornish, K. E. Callon, A. R. King, G. J. S. Cooper, and I. R. Reid, “Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice,” The American Journal of Physiology Links, vol. 275, no. 4, pp. E694–E699, 1998.
View at: Google ScholarJ. Cornish, K. E. Gallon, C. Q. Lin et al., “Dissociation of the effects of amylin on osteoblast proliferation and bone resorption,” The American Journal of Physiology, vol. 274, no. 5, pp. E827–E833, 1998.
View at: Google ScholarM. Zaidi, V. S. Shankar, C. L.-H. Huang, M. Paizanas, and S. R. Bloom, “Amylin in bone conservation: current evidence and hypothetical considerations,” Trends in Endocrinology and Metabolism, vol. 4, no. 8, pp. 255–259, 1993.
View at: Publisher Site | Google ScholarJ. Cornish and I. R. Reid, “Effects of amylin and adrenomedullin on the skeleton,” Journal of Musculoskeletal & Neuronal Interactions, vol. 2, no. 1, pp. 15–24, 2001.
View at: Google ScholarJ. Bronsky, R. Prusa, and J. Nevoral, “The role of amylin and related peptides in osteoporosis,” Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 373, no. 1–2, pp. 9–16, 2006.
View at: Publisher Site | Google ScholarJ. Cornish, K. E. Callon, U. Bava et al., “Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice,” Journal of Endocrinologyl, vol. 170, no. 1, pp. 251–257, 2001.
View at: Publisher Site | Google ScholarJ. Cornish, K. E. Callon, U. Bava et al., “Preptin, another peptide product of the pancreatic -cell, is osteogenic in vitro and in vivo,” American Journal of Physiology. Endocrinology and Metabolism, vol. 292, no. 1, pp. E117–E122, 2007.
View at: Publisher Site | Google ScholarA. Koerner and J. Kratzsch, “Kiess W. Adipocytokines: leptin—the classical, resistin—the controversical, adiponectin—the promising, and more to come,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 19, no. 4, pp. 525–546, 2005.
View at: Publisher Site | Google ScholarX. H. Luo, L. J. Guo, H. Xie et al., “Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway,” Journal of Bone and Mineral Research, vol. 21, no. 10, pp. 1648–1656, 2006.
View at: Publisher Site | Google ScholarY. Shinoda, M. Yamaguchi, N. Ogata et al., “Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways,” Journal of Cellular Biochemistry, vol. 99, no. 1, pp. 196–208, 2006.
View at: Publisher Site | Google ScholarL. Lenchik, T. C. Register, F. C. Hsu et al., “Adiponectin as a novel determinant of bone mineral density and visceral fat,” Bone, vol. 33, no. 4, pp. 646–651, 2003.
View at: Publisher Site | Google ScholarJ. B. Richards, A. M. Valdes, K. Burling, U. C. Perks, T. D. Spector et al., “Serum adiponectin and bone mineral density in women,” Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 4, pp. 1517–1523, 2007.
View at: Publisher Site | Google ScholarL. Thommesen, A. K. Stunes, M. Monjo et al., “Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism,” Journal of Cellular Biochemistry, vol. 99, no. 3, pp. 824–834, 2006.
View at: Publisher Site | Google ScholarL. Patel, A. C. Buckels, I. J. Kinghorn et al., “Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators,” Biochemical and Biophysical Research Communications, vol. 300, no. 2, pp. 472–476, 2003.
View at: Publisher Site | Google ScholarK. W. Oh, W. Y. Lee, E. J. Rhee et al., “The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men,” Clinical Endocrinology, vol. 63, no. 2, pp. 131–138, 2005.
View at: Publisher Site | Google ScholarR. J. Bollag, Q. Zhong, K. H. Ding et al., “Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects,” Molecular and Cellular Endocrinology, vol. 177, no. 1–2, pp. 35–41, 2001.
View at: Publisher Site | Google ScholarJ. C. Brown, V. Mutt, and R. A. Pederson, “Further purification of a polypeptide demonstrating enterogastrone activity,” Journal of Physiology, vol. 209, no. 1, pp. 57–64, 1970.
View at: Google ScholarR. J. Bollag, Q. Zhong, P. Phillips et al., “Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors,” Endocrinology, vol. 141, no. 3, pp. 1228–1235, 2000.
View at: Publisher Site | Google ScholarQ. Zhong, T. Itokawa, S. Sridhar et al., “Effects of glucose-dependent insulinotropic peptide on osteoclast function,” American Journal of Physiology—Endocrinology and Metabolism, vol. 292, no. 2, pp. E543–E548, 2007.
View at: Publisher Site | Google ScholarD. Xie, H. Cheng, M. Hamrick et al., “Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover,” Bone, vol. 37, no. 6, pp. 759–769, 2005.
View at: Publisher Site | Google ScholarK. Tsukiyama, Y. Yamada, C. Yamada et al., “Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion,” Molecular Endocrinology, vol. 20, no. 7, pp. 1644–1651, 2006.
View at: Publisher Site | Google ScholarD. Xie, Q. Zhong, K.-H. Ding et al., “Glucose-Dependent Insulinotropic Peptide-Overexpressing Transgenic Mice Have Increased Bone Mass,” Bone, vol. 40, pp. 1352–1360, 2007.
View at: Google ScholarK. Miyawaki, Y. Yamada, H. Yano et al., “Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 26, pp. 14843–14847, 1999.
View at: Publisher Site | Google ScholarK. Miyawaki, Y. Yamada, N. Ban et al., “Inhibition of gastric inhibitory polypeptide signaling prevents obesity,” Nature Medicine, vol. 8, pp. 738–742, 2002.
View at: Publisher Site | Google ScholarX. Shi, M. Hamrick, B. Kang et al., The Impact of Aging on Stem Cell Differentiation Induced by Nutrition-Related Hormones, International Federation of Adipose Therapeutics and Science, Baton Rouge, La, USA, 2006.
M. W. Hamrick, “Invited perspective: leptin and bone—a consensus emerging?” Bonekey Osteovision, vol. 4, pp. 99–107, 2007.
View at: Google ScholarR. L. Leshan, M. Björnholm, H. Münzberg, and M. G. Myers Jr., “Leptin receptor signaling and action in the central nervous system,” Obesity (Silver Spring), vol. 14, 5, pp. 208–212, 2006.
View at: Google ScholarB. M. Spiegelman and J. S. Flier, “Obesity and the regulation of energy balance,” Cell, vol. 104, no. 4, pp. 531–543, 2001.
View at: Publisher Site | Google ScholarS. Collins, C. M. Kuhn, A. E. Petro, A. G. Swick, B. A. Chrunyk, and R. S. Surwit, “Role of leptin in fat regulation,” Nature, vol. 380, no. 6576, p. 677, 1996.
View at: Publisher Site | Google ScholarM. Hamrick, M. Della Fera, Y.-H. Choi, D. Hartzell, C. Pennington, and C. Baile, “Injections of leptin into rat ventromedial hypothalamus increase adipocyte apoptosis in peripheral fat and in bone marrow,” Cell and Tissue Research, vol. 327, no. 1, pp. 133–141, 2007.
View at: Publisher Site | Google ScholarS. Collins and R. S. Surwit, “The -adrenergic receptors and the control of adipose tissue metabolism and thermogenesis,” Recent Progress in Hormone Research, vol. 56, pp. 309–328, 2001.
View at: Publisher Site | Google ScholarY. C. Ma and X. Y. Huang, “Novel signaling pathway through the -adrenergic receptor,” Trends in Cardiovascular Medicine, vol. 12, no. 1, pp. 46–49, 2002.
View at: Publisher Site | Google ScholarM. W. Hamrick, C. Pennington, D. Newton, D. Xie, and C. Isales, “Leptin deficiency produces contrasting phenotypes in bones of the limb and spine,” Bone, vol. 34, no. 3, pp. 376–383, 2004.
View at: Publisher Site | Google ScholarM. W. Hamrick, M. A. Della-Fera, Y. H. Choi, C. Pennington, D. Hartzell, and C. A. Baile, “Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice,” Journal of Bone and Mineral Research, vol. 20, no. 6, pp. 994–1001, 2005.
View at: Publisher Site | Google ScholarT. Thomas, F. Gori, S. Khosla, M. D. Jensen, B. Burguera, and B. L. Riggs, “Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes,” Endocrinology, vol. 140, no. 4, pp. 1630–1638, 1999.
View at: Publisher Site | Google ScholarP. Laharrague, D. Larrouy, A. M. Fontanilles et al., “High expression of leptin by human bone marrow adipocytes in primary culture,” FASEB Journal, vol. 12, no. 9, pp. 747–752, 1998.
View at: Google ScholarM. W. Hamrick, K. H. Ding, C. Pennington et al., “Age-related loss of muscle mass and bone strength in mice is associated with a decline in physical activity and serum leptin,” Bone, vol. 39, no. 4, pp. 845–853, 2006.
View at: Publisher Site | Google ScholarJ. Lin, H. B. Arnold, M. A. Della-Fera, M. J. Azain, D. L. Hartzell, and C. A. Baile, “Myostatin knockout in mice increases myogenesis and decreases adipogenesis,” Biochemical and Biophysical Research Communications, vol. 291, no. 3, pp. 701–706, 2002.
View at: Publisher Site | Google ScholarA. C. McPherron and S. J. Lee, “Suppression of body fat accumulation in myostatin-deficient mice,” The Journal of Clinical Investigation, vol. 109, pp. 595–601, 2002.
View at: Publisher Site | Google ScholarM. W. Hamrick, C. Pennington, C. N. Webb, and C. M. Isales, “Resistance to body fat gain in double-muscled mice fed a high-fat diet,” International Journal of Obesity, vol. 30, no. 5, pp. 868–870, 2006.
View at: Publisher Site | Google ScholarB. Zhao, R. J. Wall, and J. Yang, “Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance,” Biochemical and Biophysical Research Communications, vol. 337, no. 1, pp. 248–255, 2005.
View at: Publisher Site | Google ScholarM. Schuelke, K. R. Wagner, L. E. Stolz et al., “Myostatin mutation associated with gross muscle hypertrophy in a child,” The New England Journal of Medicine, vol. 350, no. 26, pp. 2682–2688, 2004.
View at: Publisher Site | Google ScholarG. Milan, E. Dalla Nora, C. Pilon et al., “Changes in muscle myostatin expression in obese subjects after weight loss,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 6, pp. 2724–2727, 2004.
View at: Publisher Site | Google ScholarJ. N. Artaza, S. Bhasin, T. R. Magee et al., “Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells,” Endocrinology, vol. 146, no. 8, pp. 3547–3557, 2005.
View at: Publisher Site | Google ScholarH. S. Kim, L. Liang, R. G. Dean, D. B. Hausman, D. L. Hartzell, and C. A. Baile, “Inhibition of preadipocyte differentiation by myostatin treatment in 3T3-L1 cultures,” Biochemical and Biophysical Research Communications, vol. 281, no. 4, pp. 902–906, 2001.
View at: Publisher Site | Google ScholarA. Rebbapragada, H. Benchabane, J. L. Wrana, A. J. Celeste, and L. Attisano, “Myostatin signals through a transforming growth factor -like signaling pathway to block adipogenesis,” Molecular and Cellular Biology, vol. 23, no. 20, pp. 7230–7242, 2003.
View at: Publisher Site | Google ScholarK. M. Lai, M. Gonzalez, W. T. Poueymirou et al., “Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy,” Molecular and Cellular Biology, vol. 24, no. 21, pp. 9295–9304, 2004.
View at: Publisher Site | Google ScholarP. Sutrave, A. M. Kelly, and S. H. Hughes, “ski can cause selective growth of skeletal muscle in transgenic mice,” Genes & Development, vol. 4, no. 9, pp. 1462–1472, 1990.
View at: Publisher Site | Google ScholarM. W. Hamrick, X. Shi, W. Zhang et al., “Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading,” Bone, vol. 40, no. 6, pp. 1544–1553, 2007.
View at: Google ScholarM. Hamrick, “Increased bone mineral density in the femora of GDF8 knockout mice,” The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, vol. 272A, no. 1, pp. 388–391, 2003.
View at: Publisher Site | Google ScholarM. W. Hamrick, C. Pennington, and C. D. Byron, “Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin),” Journal of Orthopaedic Research, vol. 21, no. 6, pp. 1025–1032, 2003.
View at: Publisher Site | Google ScholarE. K. Nicholson, S. R. Stock, M. W. Hamrick, and M. J. Ravosa, “Biomineralization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice,” Archives of Oral Biology, vol. 51, no. 1, pp. 37–49, 2006.
View at: Publisher Site | Google ScholarS. Hirai, H. Matsumoto, N. Hino, H. Kawachi, T. Matsui, and H. Yano, “Myostatin inhibits differentiation of bovine preadipocyte,” Domestic Animal Endocrinology, vol. 32, no. 1, pp. 1–14, 2007.
View at: Publisher Site | Google ScholarL. Cannarile, O. Zollo, F. D'Adamio et al., “Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormone-induced gene,” Cell Death and Differentiation, vol. 8, no. 2, pp. 201–203, 2001.
View at: Publisher Site | Google ScholarF. D'Adamio, O. Zollo, R. Moraca et al., “A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death,” Immunity, vol. 7, no. 6, pp. 803–812, 1997.
View at: Publisher Site | Google ScholarE. Ayroldi, O. Zollo, A. Macchiarulo, B. Di Marco, C. Marchetti, and C. Riccardi, “Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1,” Molecular and Cellular Biology, vol. 22, no. 22, pp. 7929–7941, 2002.
View at: Publisher Site | Google ScholarM. Shibanuma, T. Kuroki, and K. Nose, “Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor 1 and other growth factors,” The Journal of Biological Chemistry, vol. 267, no. 15, pp. 10219–10224, 1992.
View at: Google ScholarD. Berrebi, S. Bruscoli, N. Cohen et al., “Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10,” Blood, vol. 101, no. 2, pp. 729–738, 2003.
View at: Publisher Site | Google ScholarS. Bruscoli, R. Di Virgilio, V. Donato et al., “Genomic and non-genomic effects of different glucocorticoids on mouse thymocyte apoptosis,” European Journal of Pharmacology, vol. 529, no. 1–3, pp. 63–70, 2006.
View at: Publisher Site | Google ScholarP. Smit, H. Russcher, F. H. de Jong, A. O. Brinkmann, S. W. Lamberts, and J. W. Koper, “Differential regulation of synthetic glucocorticoids on gene expression levels of glucocorticoid-induced leucine zipper and interleukin-2,” Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 5, pp. 2994–3000, 2005.
View at: Publisher Site | Google ScholarD. V. Delfino, M. Agostini, S. Spinicelli, P. Vito, and C. Riccardi, “Decrease of Bcl-xL and augmentation of thymocyte apoptosis in GILZ overexpressing transgenic mice,” Blood, vol. 104, no. 13, pp. 4134–4141, 2004.
View at: Publisher Site | Google ScholarX. Shi, W. Shi, Q. Li et al., “A glucocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of mesenchymal cells,” EMBO Reports, vol. 4, no. 4, pp. 374–380, 2003.
View at: Publisher Site | Google ScholarJ. N. Beresford, C. J. Joyner, C. Devlin, and J. T. Triffitt, “The effects of dexamethasone and 1,25-dihydroxyvitamin on osteogenic differentiation of human marrow stromal cells in vitro,” Archives of Oral Biology, vol. 39, no. 11, pp. 941–947, 1994.
View at: Publisher Site | Google ScholarS. L. Cheng, J. W. Yang, L. Rifas, S. F. Zhang, and L. V. Avioli, “Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone,” Endocrinology, vol. 134, no. 1, pp. 277–286, 1994.
View at: Publisher Site | Google ScholarP. S. Leboy, J. N. Beresford, C. Devlin, and M. E. Owen, “Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures,” Journal of Cellular Physiology, vol. 146, no. 3, pp. 370–378, 1991.
View at: Publisher Site | Google ScholarA. R. Clark and M. Lasa, “Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways,” Current Opinion in Pharmacology, vol. 3, no. 4, pp. 404–411, 2003.
View at: Publisher Site | Google ScholarC. Heinrichs, M. Colli, J. A. Yanovski et al., “Effects of fasting on the growth plate: systemic and local mechanisms,” Endocrinology, vol. 138, no. 12, pp. 5359–5365, 1997.
View at: Publisher Site | Google ScholarA. F. Stewart and A. E. Broadus, “Mineral metabolism,” in Endocrinology and Metabolism, P. Felig, J. D. Baxter, A. E. Broadus, and L. A. Frohman, Eds., pp. 1317–1453, McGraw-Hill, New York, NY, USA, 2nd edition, 1987.
View at: Google ScholarC. K. Welt, J. L. Chan, J. Bullen et al., “Recombinant human leptin in women with hypothalamic amenorrhea,” The New England Journal of Medicine, vol. 351, no. 10, pp. 987–997, 2004.
View at: Publisher Site | Google ScholarB. A. Kaufman, M. P. Warren, J. E. Dominguez, J. Wang, S. B. Heymsfield, and R. N. Pierson, “Bone density and amenorrhea in ballet dancers are related to a decreased resting metabolic rate and lower leptin levels,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 6, pp. 2777–2783, 2002.
View at: Publisher Site | Google ScholarS. A. Lear, R. P. Pauly, and C. L. Birmingham, “Body fat, caloric intake, and plasma leptin levels in women with anorexia nervosa,” International Journal of Eating Disorders, vol. 26, no. 3, pp. 283–288, 1999.
View at: Publisher Site | Google ScholarJ. M. Turner, M. K. Bulsara, B. M. McDermott, G. C. Byrne, R. L. Prince, and D. A. Forbes, “Predictors of low bone density in young adolescent females with anorexia nervosa and other dieting disorders,” International Journal of Eating Disorders, vol. 30, no. 3, pp. 245–251, 2001.
View at: Publisher Site | Google ScholarK. E. Ensrud, R. L. Fullman, E. Barrett-Connor et al., “Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study,” Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 4, pp. 1998–2004, 2005.
View at: Publisher Site | Google ScholarJ. M. Johnson, J. W. Maher, I. Samuel, D. Heitshusen, C. Doherty, and R. W. Downs, “Effects of gastric bypass procedures on bone mineral density, calcium, parathyroid hormone, and vitamin D,” Journal of Gastrointestinal Surgery, vol. 9, no. 8, pp. 1106–1110, 2005.
View at: Publisher Site | Google ScholarM. Rosenbaum, R. Goldsmith, D. Bloomfield et al., “Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight,” The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3579–3586, 2005.
View at: Publisher Site | Google ScholarS. Bogdanovich, K. J. Perkins, T. O. Krag, L. A. Whittemore, and T. S. Khurana, “Myostatin propeptide-mediated amelioration of dystrophic pathophysiology,” The FASEB Journal, vol. 19, no. 6, pp. 543–549, 2005.
View at: Publisher Site | Google ScholarS. J. Lee, L. A. Reed, M. V. Davies et al., “Regulation of muscle growth by multiple ligands signaling through activin type II receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 50, pp. 18117–18122, 2005.
View at: Publisher Site | Google ScholarR. Du, Y. F. Chen, X. R. An et al., “Cloning and sequence analysis of myostatin promoter in sheep,” DNA Sequence—Journal of DNA Sequencing and Mapping, vol. 16, no. 6, pp. 412–417, 2005.
View at: Publisher Site | Google ScholarH. Gilson, O. Schakman, L. Combaret et al., “Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy,” Endocrinology, vol. 148, no. 1, pp. 452–460, 2007.
View at: Publisher Site | Google ScholarE. Ayroldi, G. Migliorati, S. Bruscoli et al., “Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor B,” Blood, vol. 98, no. 3, pp. 743–753, 2001.
View at: Publisher Site | Google Scholar